Bradford H N, Dela Cadena R A, Kunapuli S P, Dong J F, Löpez J A, Colman R W
The Sol Sherry Thrombosis Research Center and Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Blood. 1997 Aug 15;90(4):1508-15.
We and others have shown that both high and low molecular mass kininogens are able to inhibit the thrombin-induced aggregation of gel-filtered platelets, indicating that the locus for inhibition resides in the heavy chain. The inhibitory site is present in domain 3, confined to the C-terminal portion of the region encoded by exon 7 (K270-G292), and the minimal effective sequence is a heptapeptide (L271-A277; Kunapuli et al, J Biol Chem 271:11228, 1996). Kininogens inhibit thrombin binding to platelets and thus inhibit thrombin-induced aggregation. The molecular mechanism by which kininogens inhibit thrombin-induced aggregation of platelets is unknown. Thrombin has previously been shown to bind to two receptors on the platelet surface, glycoprotein (GP) Ib-IX-V complex and the hepta-spanning transmembrane receptor coupled to G protein(s). We now show that, unlike its effect on normal platelets, kininogen (2 micromol/L) did not inhibit the thrombin-induced aggregation of Bernard-Soulier platelets, which lack the GP Ib-IX-V complex, suggesting that kininogen interacts either directly or indirectly with that complex and restricts access by thrombin to this receptor. We further show that both recombinant K270-G292 polypeptide and the synthetic peptide L271-A277 derived from high molecular mass kininogen lower thrombin binding to platelets in a manner similar to monoclonal antibodies to or ligands (von Willebrand factor and echicetin) of GP Ib-IX. The anti-GP Ib-IX-V complex antibodies, TM-60 and SZ 2, can inhibit 125I-high molecular mass kininogen binding to platelets. Conversely, kininogen could block the binding of biotinylated TM-60 or of 125I-SZ 2. Kininogen inhibited the binding of biotinylated thrombin bound to a mouse fibroblast cell line transfected with the GP Ib-IX-V complex. These results indicated that kininogen binds to the GP Ib-IX-V complex modulating thrombin binding to platelets and the consequent platelet aggregation. Kininogen can thus serve as an important regulator of the early stages of platelet stimulation by thrombin.
我们和其他研究人员已表明,高分子量和低分子量激肽原均能够抑制凝血酶诱导的凝胶过滤血小板聚集,这表明抑制位点位于重链中。抑制位点存在于结构域3中,局限于外显子7编码区域(K270 - G292)的C末端部分,最小有效序列是一个七肽(L271 - A277;Kunapuli等人,《生物化学杂志》271:11228,1996)。激肽原抑制凝血酶与血小板的结合,从而抑制凝血酶诱导的聚集。激肽原抑制凝血酶诱导的血小板聚集的分子机制尚不清楚。先前已表明凝血酶可与血小板表面的两种受体结合,即糖蛋白(GP)Ib - IX - V复合物和与G蛋白偶联的七跨膜受体。我们现在表明,与对正常血小板的作用不同,激肽原(2微摩尔/升)并未抑制凝血酶诱导的Bernard - Soulier血小板聚集,这种血小板缺乏GP Ib - IX - V复合物,这表明激肽原直接或间接与该复合物相互作用,并限制凝血酶与该受体的结合。我们进一步表明,重组K270 - G292多肽和源自高分子量激肽原的合成肽L271 - A277以类似于针对GP Ib - IX的单克隆抗体或其配体(血管性血友病因子和echicetin)的方式降低凝血酶与血小板的结合。抗GP Ib - IX - V复合物抗体TM - 60和SZ 2可抑制125I - 高分子量激肽原与血小板的结合。相反,激肽原可阻断生物素化的TM - 60或125I - SZ 2的结合。激肽原抑制生物素化凝血酶与转染了GP Ib - IX - V复合物的小鼠成纤维细胞系的结合。这些结果表明,激肽原与GP Ib - IX - V复合物结合,调节凝血酶与血小板的结合以及随之而来的血小板聚集。因此,激肽原可作为凝血酶刺激血小板早期阶段的重要调节因子。